Summary:
More treatment options for Alzheimer’s disease are needed. New medications are needed to provide patients, caregivers and their physicians with more treatment options.
The MINDSET study is a global Phase III clinical research study evaluating an investigational drug for mild-to-moderate Alzheimer’s disease. The study will enroll approximately 1,150 participants in 22 countries.
The investigational medication being studied is called RVT-101. It has already been studied in multiple clinical trials involving over 1,250 individuals, including healthy subjects as well as subjects with mild-to-moderate Alzheimer’s disease. In previous studies, RVT-101 has been observed to be well-tolerated.
Researchers are investigating how effective RVT-101 in combination with donepezil (sometimes known as Aricept®) will be in helping with patients’ cognition and the ability to perform daily living activities, as compared with donepezil alone.